Table 4.

Multivariate analysis of factors predicting overall survival

Variable	Overall survival
	HR	95% CI	p
Model A
Age less (61 or greater vs than 61)	1.429	1.051–1.944	0.023
Primary tumor (T) (III/IV vs I/II)	2.370	1.517–3.702	< 0.001
Lymph nodes metastasis (N) (Yes Vs No)	1.753	1.129–2.723	0.012
TNM stage (III/IV vs I/II)	1.013	0.576–1.782	0.964
CD44 (high vs low)	1.701	1.221–2.371	0.002
Model B
Age less (61 or greater vs than 61)	1.510	1.113–2.050	0.008
Primary tumor (T) (III/IV vs I/II)	2.321	1.474–3.654	< 0.001
Lymph nodes metastasis (N) (Yes vs No)	1.706	1.086–2.682	0.021
TNM stage (III/IV vs I/II)	0.987	0.554–1.759	0.964
CD44v6 (Pos. vs Neg.)	1.168	0.848–1.609	0.340
Model C
Age less (61 or greater vs than 61)	1.493	1.100–2.027	0.010
Primary tumor (T) (III/IV vs I/II)	2.765	1.739–4.395	< 0.001
Lymph nodes metastasis (N) (yes vs no)	1.818	1.167–2.833	0.008
TNM Stage (III/IV vs I/II)	0.827	0.461–1.485	0.525
CD44v8-10 (Pos. vs Neg.)	1.694	1.234–2.326	0.001
Model E
Age less (61 or greater vs than 61)	1.509	1.112–2.047	0.008
Primary tumor (T) (III/IV vs I/II)	2.411	1.545–3.764	< 0.001
Lymph nodes metastasis (N) (yes vs no)	1.724	1.104–2.691	0.017
TNM stage (III/IV vs I/II)	0.955	0.539–1.693	0.875
ALDH1A1 (high vs low)	0.867	0.636–1.182	0.366

TNM size of primary tumor-node metastasis-distant metastasis, CD44 cluster of differentiation 44, CD44v CD44 variant, ALDH1A1 aldehyde dehydrogenase 1A1, Neg negative expression, Pos positive expression